Evidence map›Paper›PMID 41291855›Full record

ArticleJournal of translational medicine2025

Exosomes from CD133

Chao Deng, Feifei Yuan, Chengjun Li, Xiaopeng Tong, Yiming Qin, Haicheng Wen, Tian Qin, Yudong Liu, Tianding Wu, Chunyue Duan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chao Deng *Department of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Feifei YuanDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Chengjun LiKey Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, 410008, China.
Xiaopeng TongDepartment of Nuclear Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
Yiming QinDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Haicheng WenDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Tian QinDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yudong LiuDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Tianding WuDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Chunyue DuanDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yan XuDepartment of Orthopaedics, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518106, China.
Yong CaoDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China. xycaoyong@csu.edu.cn.
Hongbin LuKey Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, 410008, China. hongbinlu@csu.edu.cn.
Jianzhong HuDepartment of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, China. jianzhonghu@csu.edu.cn.ORCID http://orcid.org/0000-0002-0736-1488

Funding

Innovation-Driven Project of Central South University NO.1053320212582Key Programme NO.82030071
6 · The paper itself

Abstract

backgroundFailed regeneration following severe spinal cord injury (SCI) results from both the limited intrinsic regenerative capacity of adult neurons and an inhibitory local microenvironment. Exosome-based cell-free therapy derived from stem cells is a safer and more promising regenerative strategy. In this study, we isolated extracellular vesicles from a urine-derived stem cell subpopulation and incorporated them into an injectable, photosensitive, and highly biocompatible methacrylated carboxymethyl chitosan (CMCSMA) hydrogel to investigate their therapeutic potential for promoting functional recovery after SCI and to elucidate the underlying mechanisms.

methodsHuman urine-derived stem cells (hUSCs) were initially isolated and cultured from human urine samples. The CD133

resultsThe hUSCs were positive for CD29, CD44, CD73 and CD90 but negative for CD34 and CD45. Compared with hUSCs, the CD133

conclusionThe novel injectable CMSCMA-sExo hydrogel composite scaffold may represent a promising therapeutic approach for treating SCI using urine-derived stem cell subpopulation exosomes.

Indexed as

AC133 AntigenExosomesHydrogelsSpinal Cord InjuriesStem CellsUrineAnimalsChitosanHumansMaleNerve RegenerationRecovery of FunctionTissue ScaffoldsAC133 AntigenChitosanHydrogelsCD133CD271CMCSMA hydrogelExosomesMicrovesselsSpinal cord injuryUrine-derived stem cell subpopulations

Identifiers

PMID41291855
PMCPMC12764143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.